Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

@article{Rajani2016CombinationTW,
  title={Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.},
  author={Karishma R. Rajani and Christopher R Parrish and Timothy J Kottke and Jill M Thompson and S H Manzoor Zaidi and Liz Ilett and Kevin G Shim and Rosa-Maria Diaz and Hardev S. Pandha and Kevin J. Harrington and Matthew C. Coffey and Alan A Melcher and Richard G. Vile},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2016},
  volume={24 1},
  pages={166-74}
}
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor activity is directly associated with immune activation by virus replication in tumors. Immune mechanisms of therapy include both innate immune activation against virally infected tumor cells, and the generation of adaptive antitumor immune responses as a result of in vivo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS